CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity.
Tanaya ShreeVishnu ShankarJulian J K LohmeyerDebra K CzerwinskiJoseph G Schroers-MartinGladys M RodriguezSara BeygiAlyssa M KanegaiKaren S CorbelliEtelka GabrielDavid M KurtzMichael S KhodadoustNeel K GuptaLauren S MaedaRanjana H AdvaniAsh A AlizadehRonald LevyPublished in: Blood cancer discovery (2022)
In a large cohort of patients with B-cell lymphoma, time since anti-CD20 treatment was an independent predictor of neutralizing antibody response to COVID-19 vaccination. Comparing patients who received anti-CD20 treatment before or after vaccination, we demonstrate that vaccinating first can generate an antibody response that endures through anti-CD20-containing treatment. This article is highlighted in the In This Issue feature, p. 85.